Cargando…

A prospective study of health care resource utilisation and selected costs of schizophrenia in France

BACKGROUND: Schizophrenia is among the most burdensome and costly illnesses worldwide. To estimate the cost of schizophrenia in France, a longitudinal study was carried out between 1998 and 2002. The main objective of this study was to describe and update the cost of schizophrenia in a longitudinal,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarlon, Emmanuelle, Heider, Dirk, Millier, Aurélie, Azorin, Jean-Michel, König, Hans-Helmut, Hansen, Karina, Angermeyer, Matthias C, Aballéa, Samuel, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459707/ https://www.ncbi.nlm.nih.gov/pubmed/22909284 http://dx.doi.org/10.1186/1472-6963-12-269

Ejemplares similares

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
por: Millier, Aurelie, et al.
Publicado: (2011)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey
por: Angermeyer, Matthias C, et al.
Publicado: (2013)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC
por: Siani, Carole, et al.
Publicado: (2015)

Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations
por: Thokagevistk, Katia, et al.
Publicado: (2016)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries
por: Millier, Aurelie, et al.
Publicado: (2013)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

Cultural Variations in Public Beliefs about Mental Disorders: A Comparison between Tunisia and Germany
por: Angermeyer, Matthias C., et al.
Publicado: (2020)

Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data
por: Rahhali, Nora, et al.
Publicado: (2015)

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review
por: Azaiez, Chiraz, et al.
Publicado: (2018)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Healthcare resource use in schizophrenia, EuroSC findings
por: Millier, A., et al.
Publicado: (2017)

Evaluation of patients on sertindole treatment after failure of other antipsychotics: A retrospective analysis
por: Azorin, Jean-Michel, et al.
Publicado: (2008)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Factors influencing the COVID-19 daily deaths' peak across European countries
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
por: Hawken, Natalia, et al.
Publicado: (2017)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs
por: Moffa, Giusi, et al.
Publicado: (2023)

Market access pathways for cell therapies in France
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Cost analysis of adverse events associated with non-small cell lung cancer management in France
por: Chouaid, Christos, et al.
Publicado: (2017)

Health economic evaluation of gene replacement therapies: methodological issues and recommendations
por: Aballéa, Samuel, et al.
Publicado: (2020)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
por: Escobar Cervantes, Carlos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1mnmjjm21csn9a7q9sb8v27n1b